Les fluoroquinolones en pédiatrie

Gendrel, D.; Moulin, F.; Sauvé-Martin, H; Raymond, Josette

doi:10.1016/s0399-077x(01)00189-5

Médecine et Maladies Infectieuses

2001

DOI: 10.1016/s0399-077x(01)00189-5

|View full text |Cite

Les fluoroquinolones en pédiatrie

D. Gendrel

F. Moulin

H Sauvé-Martin

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2001

2003

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These drugs are occasionally used to treat pediatric patients with severe infections for which no other treatment is possible, especially per os. Potential indications in pediatrics are CF-related infections, salmonellosis, and shigellosis due to resistant strains; severe neonatal infections due to members of the family Enterobacteriaceae; complicated urinary tract infections; and severe infections due to resistant strains in immunocompromised patients (13,31).…”

mentioning

confidence: 99%

Population Pharmacokinetics of Ciprofloxacin in Pediatric and Adolescent Patients with Acute Infections

Payen

Serreau²,

Munck³

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The aim of the present study was to characterize the population pharmacokinetics of ciprofloxacin in patients with and without cystic fibrosis ranging in age from 1 day to 24 years and to propose a limited sampling strategy to estimate individual pharmacokinetic parameters. Patients were divided into four groups according to the treatment schedule. They received ciprofloxacin by intravenous infusion (30 min) or by the oral route. The number of samples collected from each patient ranged from 1 to 12. The population parameters were computed for an initial group of 37 patients. The data were analyzed by nonlinear mixed-effect modeling by use of a two-compartment structural model. The interindividual variability in clearance (CL) was partially explained by a dependence on age and the patient's clinical status. In addition, a significant relationship was found between weight and the initial volume of distribution. Eighteen additional patients were used for model validation and evaluation of limited sampling strategies. When ciprofloxacin was administered intravenously, sampling at a single point (12 h after the start of infusion) allowed the precise and accurate estimation of CL and the elimination half-life, as well as the ciprofloxacin concentration at the end of the infusion. It should be noted that to take into account the presence of a lag time after oral administration, a schedule based on two sampling times of 1 and 12 h is needed. The results of this study combine relationships between ciprofloxacin pharmacokinetic parameters and patient covariates that may be useful for dose adjustment and a convenient sampling procedure that can be used for further studies.Hospitalized pediatric patients with serious infections are a challenge to the clinician who takes care of them. Indeed, the pharmacokinetics of most drugs are age dependent (4,8,32). Maturation of metabolic pathways takes place at different rates; the level of metabolic clearance of drugs is very low at birth and then increases to reach a maximum at about age 1 year, when it can exceed that for adults. Renal blood flow, the glomerular filtration rate, and tubular secretion are all lower at birth and then increase to approach the values for adults by the end of the first year of life. There are also significant changes in drug disposition and in the quantity and quality of plasma proteins in the first few years of life. Moreover, pharmacoki-

show abstract

mentioning

confidence: 99%

Population Pharmacokinetics of Ciprofloxacin in Pediatric and Adolescent Patients with Acute Infections

Payen

Serreau²,

Munck³

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Ostéomyélites aiguës de l’enfant drépanocytaire en zone tropicale : intérêt de l’utilisation des fluoroquinolones par voie orale

Gbadoé

Dogba

Dagnra

et al. 2001

Archives de Pédiatrie

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Les fluoroquinolones en pédiatrie

Cited by 2 publications

References 55 publications

Population Pharmacokinetics of Ciprofloxacin in Pediatric and Adolescent Patients with Acute Infections

Population Pharmacokinetics of Ciprofloxacin in Pediatric and Adolescent Patients with Acute Infections

Ostéomyélites aiguës de l’enfant drépanocytaire en zone tropicale : intérêt de l’utilisation des fluoroquinolones par voie orale

Contact Info

Product

Resources

About